CR20190209A - Inmunoglobulinas y usos de estas - Google Patents

Inmunoglobulinas y usos de estas

Info

Publication number
CR20190209A
CR20190209A CR20190209A CR20190209A CR20190209A CR 20190209 A CR20190209 A CR 20190209A CR 20190209 A CR20190209 A CR 20190209A CR 20190209 A CR20190209 A CR 20190209A CR 20190209 A CR20190209 A CR 20190209A
Authority
CR
Costa Rica
Prior art keywords
relates
therapeutic
life
subject
methods
Prior art date
Application number
CR20190209A
Other languages
English (en)
Inventor
Shamina M Rangwala
Yue-Mei Zhang
Raymond J Patch
Katharine E D'aquino
James N Leonard
Mark Wall
Rui Zhang
Mark Macielag
Michael J Hunter
Ronald V Swanson
Wenying Jian
Martin A Case
Wilson Edwards
Raul C Camacho
Ellen Chi
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR20190209A publication Critical patent/CR20190209A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

La presente invención se relaciona con una plataforma de anticuerpos monoclonales diseñada para acoplarse a péptidos terapéuticos para aumentar la vida media del péptido terapéutico en un sujeto. La invención se relaciona también con composiciones farmacéuticas y con métodos para usarlas.The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
CR20190209A 2016-10-27 2017-10-26 Inmunoglobulinas y usos de estas CR20190209A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662413613P 2016-10-27 2016-10-27
US201662413586P 2016-10-27 2016-10-27
PCT/US2017/058462 WO2018081375A1 (en) 2016-10-27 2017-10-26 Immunoglobulins and uses thereof

Publications (1)

Publication Number Publication Date
CR20190209A true CR20190209A (es) 2019-08-21

Family

ID=62020814

Family Applications (3)

Application Number Title Priority Date Filing Date
CR20190210A CR20190210A (es) 2016-10-27 2017-10-26 Compuestos del péptido tirosina tirosina cíclico como moduladores de receptores de neuropéptido y
CR20190208A CR20190208A (es) 2016-10-27 2017-10-26 Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y
CR20190209A CR20190209A (es) 2016-10-27 2017-10-26 Inmunoglobulinas y usos de estas

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CR20190210A CR20190210A (es) 2016-10-27 2017-10-26 Compuestos del péptido tirosina tirosina cíclico como moduladores de receptores de neuropéptido y
CR20190208A CR20190208A (es) 2016-10-27 2017-10-26 Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y

Country Status (37)

Country Link
US (14) US10961293B2 (es)
EP (4) EP3988123A1 (es)
JP (6) JP7090077B2 (es)
KR (6) KR102653381B1 (es)
CN (3) CN109890410A (es)
AU (5) AU2017348180A1 (es)
BR (3) BR112019008500A2 (es)
CA (3) CA3041672A1 (es)
CL (3) CL2019001110A1 (es)
CO (3) CO2019003938A2 (es)
CR (3) CR20190210A (es)
CY (1) CY1124732T1 (es)
DK (1) DK3532486T3 (es)
DO (3) DOP2019000107A (es)
EC (3) ECSP19029835A (es)
ES (1) ES2897480T3 (es)
HR (1) HRP20211626T1 (es)
HU (1) HUE056442T2 (es)
IL (4) IL266202B2 (es)
JO (3) JOP20190097A1 (es)
LT (1) LT3532486T (es)
MA (3) MA46672A (es)
MD (1) MD3532486T2 (es)
MX (4) MX2019004955A (es)
NI (2) NI201900043A (es)
PE (3) PE20190917A1 (es)
PH (3) PH12019500723A1 (es)
PL (1) PL3532486T3 (es)
PT (1) PT3532486T (es)
RS (1) RS62677B1 (es)
SA (3) SA519401646B1 (es)
SG (4) SG11201902886SA (es)
SI (1) SI3532486T1 (es)
TW (4) TWI773699B (es)
UY (3) UY37455A (es)
WO (3) WO2018081375A1 (es)
ZA (1) ZA202200648B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3912986B1 (en) 2013-12-18 2023-12-13 President and Fellows of Harvard College Crp capture/detection of bacteria
JOP20190097A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها
US10875902B2 (en) 2018-04-25 2020-12-29 Janssen Pharmaceutica Nv Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
TW202014433A (zh) * 2018-04-25 2020-04-16 比利時商健生藥品公司 類升糖素肽１（ｇｌｐ－１）融合肽偶合環狀酪酪肽接合物及其用途
WO2020262590A1 (ja) * 2019-06-28 2020-12-30 味の素株式会社 環状ペプチドの製造方法
WO2021094259A1 (en) 2019-11-11 2021-05-20 Boehringer Ingelheim International Gmbh Npy2 receptor agonists
CN111494606B (zh) * 2020-04-24 2021-12-14 广州医科大学 神经肽y的新应用
PE20231566A1 (es) 2020-08-07 2023-10-04 Boehringer Ingelheim Int Agonistas del receptor npy2 solubles
CN115073556A (zh) * 2021-03-12 2022-09-20 上海天慈生命科学发展有限公司 一类阿片/神经肽ff受体多靶点环肽分子及其制备和应用
US20230015478A1 (en) * 2021-06-14 2023-01-19 Resolute Bio, Inc. Glp-1 receptor agonists having improved pharmacological and drug delivery properties
WO2023097363A1 (en) * 2021-11-30 2023-06-08 Garvan Institute Of Medical Research Improved binding proteins and uses thereof
CN115028551B (zh) * 2022-07-15 2024-01-05 成都普康生物科技有限公司 一种叠氮-九甘醇-丙酸的制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2434149A1 (fr) 1978-06-22 1980-03-21 Parcor Nouveaux derives de la l-cysteine
US5393669A (en) 1993-02-05 1995-02-28 Martek Biosciences Corp. Compositions and methods for protein structural determinations
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
WO2005077094A2 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
EP1718671A2 (en) 2004-02-23 2006-11-08 Rheoscience A/S Peptide yy analogues
JP2007531713A (ja) * 2004-03-17 2007-11-08 ７ティーエム ファーマ エイ／エス 治療的介入のためのｙ２選択性レセプターアゴニスト
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
US20090186817A1 (en) * 2006-03-21 2009-07-23 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
KR20090074787A (ko) 2006-10-05 2009-07-07 센토코 오르토 바이오테크 인코포레이티드 섬유증 치료용 ｃｃｒ2 길항제
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
WO2009085462A1 (en) 2007-12-19 2009-07-09 Centocor, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
CA2742710A1 (en) 2008-11-04 2010-05-14 Janssen Pharmaceutica Nv Crhr2 peptide agonists and uses thereof
BRPI0921230A2 (pt) * 2008-11-05 2018-10-30 Hoffmann La Roche agonistas de receptor de neuropeptídeos-2 (y-2r) e usos dos mesmo.
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
SG177609A1 (en) 2009-07-13 2012-02-28 Zealand Pharma As Acylated glucagon analogues
US20130040877A1 (en) 2009-09-18 2013-02-14 Novo Nordisk A/S Long-acting y2 receptor agonists
SG184427A1 (en) 2010-04-20 2012-11-29 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
EP2621950A4 (en) * 2010-09-27 2015-09-02 Janssen Biotech Inc ANTIBODIES FOR BINDING HUMAN COLLAGEN II
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
JP6167040B2 (ja) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
PL3395836T3 (pl) * 2011-01-28 2021-12-13 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
KR101577734B1 (ko) * 2011-06-17 2015-12-29 한미사이언스 주식회사 옥신토모듈린과 면역글로불린 단편을 포함하는 결합체 및 그의 용도
PL2773671T3 (pl) 2011-11-04 2022-01-24 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
CN104428006B (zh) 2012-07-04 2017-09-08 弗·哈夫曼-拉罗切有限公司 共价连接的抗原‑抗体缀合物
SG11201503370WA (en) * 2012-11-06 2015-05-28 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
CN105007941B (zh) 2012-12-27 2019-01-25 赛诺菲 抗-lamp1抗体和抗体药物偶联物及其用途
CN105073781A (zh) 2013-01-11 2015-11-18 加州生物医学研究所 牛融合抗体
RU2015144632A (ru) 2013-05-02 2017-06-07 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Терапевтические пептиды
ES2719584T3 (es) 2014-04-11 2019-07-11 Medimmune Llc Compuestos conjugados que comprenden anticuerpos modificados por ingeniería genética con cisteína
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
WO2016018931A1 (en) 2014-07-30 2016-02-04 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EA201891084A1 (ru) 2015-11-02 2019-10-31 Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение
JOP20190097A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها
TW202014433A (zh) * 2018-04-25 2020-04-16 比利時商健生藥品公司 類升糖素肽１（ｇｌｐ－１）融合肽偶合環狀酪酪肽接合物及其用途

Also Published As

Publication number Publication date
CA3041672A1 (en) 2018-05-03
AU2022200089B2 (en) 2023-11-16
US20180125998A1 (en) 2018-05-10
KR102573684B1 (ko) 2023-09-04
JP2022137031A (ja) 2022-09-21
US20190345214A1 (en) 2019-11-14
BR112019008500A2 (pt) 2019-07-09
US10961293B2 (en) 2021-03-30
US20190367577A1 (en) 2019-12-05
US10640544B2 (en) 2020-05-05
RS62677B1 (sr) 2021-12-31
DOP2019000178A (es) 2020-02-16
KR102653381B1 (ko) 2024-04-02
AU2017348175A1 (en) 2019-04-18
PE20191079A1 (es) 2019-08-20
CN109890410A (zh) 2019-06-14
US20180127476A1 (en) 2018-05-10
EP3534928A1 (en) 2019-09-11
UY37457A (es) 2018-04-30
KR20230129194A (ko) 2023-09-06
CR20190210A (es) 2019-05-27
US10787495B2 (en) 2020-09-29
SA519401646B1 (ar) 2021-12-26
AU2017348180A1 (en) 2019-04-18
AU2017348172A1 (en) 2019-04-18
WO2018081367A1 (en) 2018-05-03
KR20190073492A (ko) 2019-06-26
CL2019001110A1 (es) 2019-07-05
JP7090077B2 (ja) 2022-06-23
TWI794189B (zh) 2023-03-01
IL266202A (en) 2019-06-30
UY37456A (es) 2018-04-30
LT3532486T (lt) 2021-11-10
SG11201902873RA (en) 2019-05-30
US11767354B2 (en) 2023-09-26
US20180117170A1 (en) 2018-05-03
MX2019004952A (es) 2019-06-24
BR112019008417A2 (pt) 2019-09-03
US10858413B2 (en) 2020-12-08
WO2018081375A1 (en) 2018-05-03
IL266206A (en) 2019-06-30
SG11201902886SA (en) 2019-05-30
US20210094998A1 (en) 2021-04-01
JOP20190096B1 (ar) 2023-09-17
US11732019B2 (en) 2023-08-22
CO2019004203A2 (es) 2019-05-10
CR20190208A (es) 2019-05-27
CO2019004186A2 (es) 2019-05-10
SI3532486T1 (sl) 2021-12-31
KR20240046290A (ko) 2024-04-08
US20190298849A1 (en) 2019-10-03
CN110099692A (zh) 2019-08-06
ECSP19029942A (es) 2019-05-31
US20190263879A1 (en) 2019-08-29
PE20190916A1 (es) 2019-06-26
AU2021269420B2 (en) 2023-11-23
EP3532092A4 (en) 2020-07-01
CY1124732T1 (el) 2022-07-22
US10428134B2 (en) 2019-10-01
SA519401642B1 (ar) 2022-03-07
PH12019500723A1 (en) 2019-11-11
US20240018208A1 (en) 2024-01-18
PH12019500749A1 (en) 2019-11-11
EP3534928A4 (en) 2020-08-12
AU2017348172B2 (en) 2021-10-07
JOP20190097A1 (ar) 2019-04-28
PE20190917A1 (es) 2019-06-26
US20200385439A1 (en) 2020-12-10
UY37455A (es) 2018-04-30
JOP20190095A1 (ar) 2019-04-28
CN110099692B (zh) 2024-03-12
WO2018081370A1 (en) 2018-05-03
PL3532486T3 (pl) 2022-01-31
EP3532486A1 (en) 2019-09-04
MA46672A (fr) 2019-09-04
US10968265B2 (en) 2021-04-06
ECSP19029835A (es) 2019-05-31
EP3532092A1 (en) 2019-09-04
HRP20211626T1 (hr) 2022-02-04
BR112019008351A2 (pt) 2019-10-01
US20210206822A1 (en) 2021-07-08
AU2021269420A1 (en) 2021-12-16
NI201900043A (es) 2019-10-25
ES2897480T3 (es) 2022-03-01
TWI781118B (zh) 2022-10-21
DOP2019000107A (es) 2019-09-30
JOP20190096A1 (ar) 2019-04-28
HUE056442T2 (hu) 2022-02-28
SG11201902879SA (en) 2019-05-30
JP2019534283A (ja) 2019-11-28
EP3988123A1 (en) 2022-04-27
MA46665B1 (fr) 2021-09-30
PT3532486T (pt) 2021-11-19
MA46718A (fr) 2019-09-11
EP3532486A4 (en) 2020-06-24
MX2019004955A (es) 2019-06-24
MA46665A (fr) 2019-09-04
KR20240046621A (ko) 2024-04-09
JP2020510606A (ja) 2020-04-09
JP7231539B2 (ja) 2023-03-01
EP3532486B1 (en) 2021-09-22
DK3532486T3 (da) 2021-10-18
TW202304972A (zh) 2023-02-01
DOP2019000106A (es) 2019-09-30
NI201900044A (es) 2019-09-09
JP7387431B2 (ja) 2023-11-28
KR102653376B1 (ko) 2024-04-02
CN110036022A (zh) 2019-07-19
US20210163566A1 (en) 2021-06-03
MD3532486T2 (ro) 2022-01-31
ECSP19029995A (es) 2019-05-31
CA3041674A1 (en) 2018-05-03
CL2019001136A1 (es) 2019-07-05
JP2024020405A (ja) 2024-02-14
IL266202B2 (en) 2023-09-01
TW201827081A (zh) 2018-08-01
CA3041046A1 (en) 2018-05-03
AU2022200089A1 (en) 2022-02-03
US11591379B2 (en) 2023-02-28
TWI773699B (zh) 2022-08-11
US11401315B2 (en) 2022-08-02
SG10202107777XA (en) 2021-08-30
US20230365644A1 (en) 2023-11-16
JP2023012467A (ja) 2023-01-25
AU2017348175B2 (en) 2021-08-26
IL266202B1 (en) 2023-05-01
IL266204A (en) 2019-06-30
KR20190072616A (ko) 2019-06-25
US10968264B2 (en) 2021-04-06
CL2019001129A1 (es) 2019-07-05
MX2019004954A (es) 2019-06-24
PH12019500906A1 (en) 2020-01-20
MX2023005465A (es) 2023-05-22
KR20190072615A (ko) 2019-06-25
US20200283491A1 (en) 2020-09-10
IL301843A (en) 2023-06-01
CO2019003938A2 (es) 2019-04-30
TW201829455A (zh) 2018-08-16
TW201827456A (zh) 2018-08-01
ZA202200648B (en) 2024-02-28
SA519401647B1 (ar) 2022-01-26
EP3532486B8 (en) 2022-01-12
JP2019534281A (ja) 2019-11-28

Similar Documents

Publication Publication Date Title
CR20190209A (es) Inmunoglobulinas y usos de estas
ECSP18082207A (es) Neoantígenos y métodos de su uso
EA202190808A2 (ru) Составы антител к cd38 для подкожного введения и их применение
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
CL2017003261A1 (es) Factor xi anticuerpos y métodos de uso
EA201892294A1 (ru) Антитела и композиции против tim-3
BR112016023948A2 (pt) proteínas fc multiméricas
MX2017012352A (es) Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos.
MY185802A (en) Antibody formulation
AR101829A1 (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1
EA201790239A1 (ru) Молекула-носитель для антигенов
AR107290A1 (es) ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
MX2017014056A (es) Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.
NZ723858A (en) Anti-human ox40l antibodies, uses & methods
CY1121895T1 (el) Σκευασματα διαλυματος κατασκευασμενων αντισωματων anti-il-23p19
MA49122A (fr) Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
CO2019003759A2 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
MX2017003216A (es) Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
PH12018500159A1 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
BR112016029935A2 (pt) ?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo?
MX2018014716A (es) Anticuerpos anti-tnfrsf25.
AR110106A1 (es) Inmunoglobulinas y usos de estas
EA201991022A1 (ru) Иммуноглобулины и их применение